drugset
drugset / Trial / NCT00924508

Hydrogel Patch for the Treatment of Eczema

NCT00924508 ↗

Terminated 23 enrolled University of California, San Francisco Teikoku Pharma USA, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this clinical study is to determine whether occlusion of triamcinolone 0.1% cream (TAC) with hydrogel patch improves its efficacy in treating eczema. A secondary objective is to determine whether eczema improves under occlusion with hydrogel patch alone, without TAC.

Timeline

Start
2008-07
Primary completion
2011-09
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Acetonide Other / unclassified 0.1 % Topical

Indications

dermatitis